Nanopharma Cerulean Advances Cancer Particle, Looks Ahead To siRNA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Nanotech platform company Cerulean Pharma Inc. has a high-quality problem. The Cambridge, Mass., start-up is poised to take its lead candidate into Phase IIb cancer trials, but the young company must choose among several cancer types in which the nanoparticle shows go-ahead activity
You may also be interested in...
Variety Of Novel Approaches Marks Next-Gen Cancer Therapies At AACR
The annual meeting of the American Association for Cancer Research has always been a venue for biotechs to display innovative approaches to treating cancer – perhaps catching the eye of an investor – and the 2011 meeting didn't disappoint.
Variety Of Novel Approaches Marks Next-Gen Cancer Therapies At AACR
The annual meeting of the American Association for Cancer Research has always been a venue for biotechs to display innovative approaches to treating cancer – perhaps catching the eye of an investor – and the 2011 meeting didn't disappoint.
FDA Not Ready For The Nanotechnology Surge; Infrastructure - Not Technical Capability - Is The Challenge, Hamburg Says
FDA Commissioner Margaret Hamburg said the agency's infrastructure is not where it needs to be in order to pursue nanotechnology initiatives